HCP 05
Medical Oncologist · Italy · Consultant
Illustrative synthetic data for prototype demonstration — not real clinical findings.
Discussion summary
Balances efficacy signals with patient selection; supportive in defined subgroups.
Key themes
Pre / post perception
Overall perception shiftPre-congress vs post-congress
3 improved · 1 declined
Perception of clinical efficacy
Confidence in the evidence
Safety / tolerability perception
Likelihood to prescribe
Familiarity with treatment
Competitive perception
Illustrative synthetic measures. Movement is shown as an observed pre/post shift, not a causal effect of the congress.
KBQs discussed
Position against each predefined questionClinical significance of the primary endpoint
What is the expert consensus regarding the clinical significance of the study’s primary endpoint results?
“The effect size here is hard to ignore — for the patients I see this is a genuinely meaningful result.”
Safety, tolerability and willingness to prescribe
How do HCP perceptions of the trial’s safety and tolerability profile impact their willingness to adopt and prescribe the treatment?
“For the right patient the balance clearly favours treating.”
Use in node-positive populations
What is the clinical consensus among HCPs regarding the use of CDK4/6 inhibitors in node-positive patient populations?
“My hesitation is cumulative tolerability across a long treatment course.”
Sequencing after adjuvant recurrence
How do clinicians approach treatment sequencing following recurrence on an adjuvant CDK4/6 inhibitor?
“Increasingly I let the molecular findings guide what I choose next.”
Compelling nature of the primary endpoint
How compelling are the primary endpoint findings in driving prospective prescribers to select this treatment over existing options?
“This is the kind of result that changes how I would sequence treatment.”
Perception of safety and tolerability
How do experts perceive the safety and tolerability profile demonstrated in the trial?
“The main adverse events are ones we already know how to manage.”